Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

Nicolas Girard; Pauline Macouillard; Danalyn Byng; Jie Meng; Friso Coerts; Shannon Hunter; Alessandria Struebing; Yan Xiong; Sarah Park; M. Inaam Haq; Olga Tymejczyk; Christos Chouaid; C. Audigier-Valette; Axelle Demaegdt; X. Quantin; Lise Bosquet; Maurice Pérol

doi:10.1007/s12325-025-03465-4

February 13, 2026Advances in TherapyOpen Access

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate clinical outcomes and treatment patterns in patients with advanced EGFR-mutant NSCLC after progression on osimertinib.
Analysis of clinical outcomes in patients after first-line osimertinib treatment.
Focus on patients with advanced or metastatic disease.
Consideration of treatment patterns observed in clinical settings.
Significant percentage of patients experience poor outcomes after progressing on osimertinib.
Findings indicate a critical need for effective second-line therapies, especially in patients with brain and liver metastases.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational data reveals poor clinical outcomes post-osimertinib in advanced NSCLC, indicating a treatment gap.

Abstract

Clinical outcomes for patients receiving 2L therapy post-osimertinib progression remain poor, highlighting an unmet need, particularly for those with brain and liver metastases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Girard et al. (2026) studied this question.

synapsesocial.com/papers/6992b4c59b75e639e9b09c10 https://doi.org/10.1007/s12325-025-03465-4

View Full Paper

Ask AI

Bookmark

Share

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading